NICE backs Roche lupus drug that supports kidney function Roche's Gazyvaro, a drug that can restore kidney function in lupus nephritis, has been cleared for use by the NHS in England and Wales.

#NICE #Roche #lupusdrug #lupus #lupusnephritis #systemiclupuserythematosus #SLE #kidneyfunction #Gazyvaro #obinutuzumab #NHS #kidneydisease #autoimmunedisorder #antiCD20antibody #NICEdraftrecommendation #Clinicaltrials #MMF #phase3clinicaltrial #ALLEGORYtrial #LupusUK #HEOR
zurl.co/cH0ta

Ultra-rapid insulin shows promise in phase 3 trial for type 1 diabetes - PharmaTimes BioChaperone Lispro demonstrates improved post-meal glucose control compared to Humalog

#Ultrarapidinsulin #phase3trial #type1diabetes #BioChaperoneLispro #THDB0206injection #postmealglucosecontrol #TonghuaDongbao #phase3clinicaltrial #ultrarapidinsulinformulation #HbA1creduction #bloodglucose #selfmonitoringbloodglucose #SMBG #diabetes #obesity
zurl.co/nlXjK

Click, Boehringer DTx for schizophrenia passes phase 3 test Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app

#digitalhealth #mentalhealth #BoehringerIngelheim #DTx #schizophrenia #phase3clinicaltrial #digitaltherapeutics #smartphonebasedapp #CT155app #ClickTherapeutics #CONVOKEstudy #CONVOKE #prescriptiondigitaltherapeutic #CAINSMAP #CT155 #antipsychotics #breakthroughdevicestatus
zurl.co/cndtD

SMC approves bimekizumab for hidradenitis suppurativa treatment - PharmaTimes The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not

#dermatology #immunology #UCB #SMC #SMCapprovel #bimekizumab #hidradenitissuppurativa #HS #hidradenitissuppurativatreatment #ScottishMedicinesConsortium #NHSScotland #HSpatients #phase3clinicaltrial #BEHEARDI #BEHEARDII #clincialstudies #patientoutcomes
pharmatimes.com/news/smc-app...

NICE recommends brentuximab vedotin plus AVD for Hodgkin lymphoma - PharmaTimes Advancing care for stage 3 or 4 Hodgkin lymphoma patients

#Haematology #oncology #Takeda #NICErecommended #brentuximabvedotin #AVD #brentuximabvedotinplusAVD #Hodgkinlymphoma #stage3Hodgkinlymphoma #stage4Hodgkinlymphoma #Hodgkinlymphomapatients #NICEdecision #phase3clinicaltrial #ECHELON1trial l
pharmatimes.com/news/nice-re...

Amivantamab plus lazertinib shows survival benefit in lung cancer - PharmaTimes Janssen drug combination extends life expectancy during trial

#oncology #Amivantamab #lazertinib #lungcancer #Janssen #phase3clinicaltrial #MARIPOSAstudy #EGFRmutatedadvancednonsmallcelllungcancer #NSCLC #nonsmallcelllungcancer #Rybrevant #Lazcluze #EuropeanLungCancerCongress #lungcancertreatment #patientoutcomes
pharmatimes.com/news/amivant...

Dermata’s Xyngari(TM) Set to Transform Acne Treatment with FDA Approval Dermata Therapeutics has received FDA approval for the proprietary name "Xyngari" (formerly DMT310), a significant milestone for the biotechnology company. Xyngari is a cutting-edge product currently ...

www.linkedin.com/pulse/dermat...

Dermata’s Xyngari(TM) Set to Transform Acne Treatment with FDA Approval

kstrategyand.com/pharma-news

#DermataTherapeutics #Xyngari #FDAApproval #AcneTreatment #BiotechInnovation #Phase3ClinicalTrial #SkincareResearch #Humanteconomy #Humantec #KStrategyand

CSL receives positive opinion for garadacimab in hereditary angioedema - PharmaTimes New treatment could revolutionise care for HAE patients

#CSL #CSLBehring #garadacimab #hereditaryangioedema #HAE #HAEpatients #EMA #CHMP #factorXIIainhibitor #HAEattacks #CHMPdecision #HAEattacks #HAEattackprevention #Phase3clinicaltrial #VANGUARDclinicaltrial #openlabelextensionstudy
pharmatimes.com/news/csl-rec...